慢性丙型肝炎感染者在初始或再治疗使用泛基因型直接抗病毒药物后病毒学失败时耐药相关替代突变的患病率:系统综述与Meta分析
该系统综述与Meta分析评估了慢性丙型肝炎感染者在使用泛基因型直接抗病毒药物(DAA)初始或再治疗发生病毒学失败后耐药相关替代突变(RAS)的患病率。纳入2014年1月至2023年7月发表的34项和22项研究,采用随机效应模型合并。初始治疗失败后RAS合并患病率:索磷布韦/维帕他韦78.0%(95%CI 62.0-92.0)、索磷布韦/达拉他韦81.0%(95%CI 67.0-93.0)、格卡瑞韦/哌仑他韦79.0%(95%CI 70.0-87.0);再治疗失败后:索磷布韦/维帕他韦/伏西瑞韦93.0%(95%CI 83.0-99.0)、格卡瑞韦/哌仑他韦100%(95%CI 92.0-100),耐药主要由NS5A抑制剂相关RAS驱动。
要点
- 初始DAA治疗失败者RAS合并患病率:索磷布韦/维帕他韦78.0%、索磷布韦/达拉他韦81.0%、格卡瑞韦/哌仑他韦79.0%。
- 再治疗失败者RAS合并患病率:索磷布韦/维帕他韦/伏西瑞韦93.0%、格卡瑞韦/哌仑他韦100%。
- 耐药主要由NS5A抑制剂相关RAS驱动,需持续监测DAA相关耐药。
核心结论
- 在初始或再治疗使用泛基因型DAA方案后发生病毒学失败的少数个体中,高比例存在至少1种RAS。
- 需要持续监测DAA相关耐药,以评估其发展的危险因素和临床影响,从而为再治疗的最佳实践策略提供依据。
研究设计与样本
- 系统综述与Meta分析,纳入34项和22项评估病毒学失败者RAS的研究,发表于2014年1月至2023年7月。
- 采用随机效应Meta分析估计RAS合并患病率。
主要发现
- 初始DAA治疗失败后RAS合并患病率:索磷布韦/维帕他韦78.0%(95%CI 62.0-92.0)、索磷布韦/达拉他韦81.0%(95%CI 67.0-93.0)、格卡瑞韦/哌仑他韦79.0%(95%CI 70.0-87.0)。
- 再治疗方案失败后RAS合并患病率:索磷布韦/维帕他韦/伏西瑞韦93.0%(95%CI 83.0-99.0)、格卡瑞韦/哌仑他韦100%(95%CI 92.0-100)。
- 耐药主要由NS5A抑制剂相关RAS驱动。
关键数值与推荐
- 初始DAA治疗失败后RAS合并患病率:索磷布韦/维帕他韦78.0%(95%CI 62.0-92.0)。
- 初始DAA治疗失败后RAS合并患病率:索磷布韦/达拉他韦81.0%(95%CI 67.0-93.0)。
- 初始DAA治疗失败后RAS合并患病率:格卡瑞韦/哌仑他韦79.0%(95%CI 70.0-87.0)。
- 再治疗失败后RAS合并患病率:索磷布韦/维帕他韦/伏西瑞韦93.0%(95%CI 83.0-99.0)。
- 再治疗失败后RAS合并患病率:格卡瑞韦/哌仑他韦100%(95%CI 92.0-100)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The advent of short-course, curative treatment with direct-acting antivirals (DAA) has given promise for the global elimination of hepatitis C virus (HCV) infections by 2030. Virological failure occurs in 2%-12% of persons receiving curative DAA treatment and may be presaged by pre-existing polymorphisms or result from selection of drug resistant variants during therapy. METHODS: We conducted a systematic review to assess the prevalence of HCV resistance associated substitutions (RAS) among individuals with chronic hepatitis C infection who had virological failure following initial or re-treatment with pan-genotypic DAA regimens. We included 34 and 22 studies assessing RAS in people with virological failure published between January 2014 and July 2023. Pooled RAS prevalence was estimated using random-effects meta-analysis. RESULTS: The pooled prevalence of RAS in people with virological failure following initial DAA treatment was 78.0% (95% confidence interval [CI]: 62.0-92.0) for sofosbuvir/velpatasvir, 81.0% (95% CI: 67.0-93.0) for sofosbuvir/daclatasvir, and 79.0% (95% CI: 70.0-87.0) for glecaprevir/pibrentasvir, with a high prevalence of resistance to the NS5A inhibitors. Among those with virological failure following re-treatment regimens, RAS were present in 93.0% (95% CI: 83.0-99.0) for sofosbuvir/velpatasvir/voxilepravir and in 100% (95% CI: 92.0-100) for glecaprevir/pibrentasvir, with resistance driven by RAS to NS5A inhibitors. DISCUSSION: At least 1 RAS is present in a high proportion of the few individuals with virological failure following initial or re-treatment with pan-genotypic DAA regimens. There is a need for ongoing surveillance for DAA-associated resistance, to assess risk factors for their development and clinical impact to inform best practice strategies for re-treatment.
引用
- Inzaule S, Easterbrook P, Latona A, et al. Prevalence of Drug Resistance Associated Substitutions in Persons With Chronic Hepatitis C Infection and Virological Failure Following Initial or Re-treatment With Pan-genotypic Direct-Acting Antivirals: A Systematic Review and Meta-analysis. Clin Infect Dis. 2024. PMID: 39361017. doi:10.1093/cid/ciae431
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。